IMPLEMENTATION OF A SHARED MEDICAL APPOINTMENT FOR OPIOID OVERDOSE EDUCATION AND NALOXONE KIT TRAINING FOR VETERANS Kristin A. Tallman, Pharm.

Size: px
Start display at page:

Download "IMPLEMENTATION OF A SHARED MEDICAL APPOINTMENT FOR OPIOID OVERDOSE EDUCATION AND NALOXONE KIT TRAINING FOR VETERANS Kristin A. Tallman, Pharm."

Transcription

1 IMPLEMENTATION OF A SHARED MEDICAL APPOINTMENT FOR OPIOID OVERDOSE EDUCATION AND NALOXONE KIT TRAINING FOR VETERANS Kristin A. Tallman, Pharm.D, BCPS Clinical Pharmacy Specialist Providence Medical Group April 28, 2017

2 DISCLOSURE Kristin A. Tallman, author of this presentation, has nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation This quality improvement project was performed to improve patient care at the VA Roseburg Healthcare System. It was approved by the Chief of Pharmacy and Pharmacy Therapeutics & Nutrition Committee. As a quality improvement project, this data is not generalizable. The contents of this presentation represent the views of the author; they do not represent the views of the Department of Veterans Affairs or the United States Government.

3 LEARNING OBJECTIVES Review rationale and key recommendations for the outpatient prescribing of naloxone Identify appropriate candidates for a naloxone prescription Discuss benefits of a shared medical appointment (SMA) for providing education to patients

4 PRE-TEST ASSESSMENT 1. Which education topics should be discussed with each patient prescribed a naloxone kit? a) How to determine if a second dose of naloxone is needed b) How to recognize signs and symptoms of an opioid overdose c) When and how to administer naloxone d) All of the above 2. Which of the following patients would benefit most from a naloxone prescription based on their risk factor(s)? a) 66 y.o. male with hypothyroidism prescribed hydrocodone as needed after a motor vehicle accident b) 52 y.o. female prescribed morphine ER with a history of sleep apnea and substance use disorder c) 31 y.o. male with generalized anxiety prescribed hydroxyzine and oxycodone as needed d) 42 y.o. female prescribed oxycodone with a history of diabetes and neuropathy 3. Which of the following is most likely to be observed after implementation of a shared medical appointment? a) Patients feel discouraged and ask fewer questions b) Patient education is provided less efficiently c) Patients report greater satisfaction with care provided d) Patient contact time with their healthcare team is decreased

5 BACKGROUND More than 1,000 people are seen in emergency departments daily for misuse of prescription opioids According to the Centers for Disease Control and Prevention (CDC), in Americans died from an overdose daily Majority of opioid overdose-related deaths occur outside of medical settings, primarily occurring in homes Deaths from prescription opioids has quadrupled since 1999 Centers for Disease Control and Prevention

6 BACKGROUND The World Health Organization, CDC, Substance Abuse and Mental Health Services Administration recommend naloxone as an essential intervention to prevent overdose Naloxone s action is to reverse opioid-mediated effects, which include respiratory depression, CNS depression, and hypotension The VA developed an Opioid Education and Naloxone Distribution (OEND) Program as a harm reduction/risk mitigation strategy Centers for Disease Control and Prevention Substance Abuse and Mental Health Services Administration United States. Department of Veterans Affairs World Health Organization

7 MEDICATION USE EVALUATION Total of 46 prescriptions for naloxone over 12 months (Apr 2015 Mar 2016) Average 4 prescriptions per month Primary Indications For Use Prescription for an opioid, dose <50 mg MED 28% Prescription for an opioid with concomitant benzodiazepine 22% History of, or active, substance use disorder 15% Prescription for an opioid, dose 50 to <100 mg MED 15% Prescription for an opioid, dose 100 mg MED 6.5% No clear indication 6.5% MED = morphine equivalent dose Education of naloxone use and administration was clearly documented in 70% of patients

8 OBJECTIVES AND GOALS Increase access to naloxone kits for patients at risk of opioid overdose Enhance patient and caregiver knowledge about opioid safety and use of naloxone Improve clinic efficiency in providing education to patients about naloxone Develop standardized approach to providing and documenting education

9 SHARED MEDICAL APPOINTMENTS Often referred to as a group visit Includes one or more healthcare professionals Typical length of appointment can be minutes Focused environment for a common condition Benefits include: Increased patient access to care Improved productivity Increased patient satisfaction Edelman D, McDuffie JR, Oddone E, et al Jaber R, Braksmajer A, Trilling JS. J Am Board Fam Med Scott JC, Conner DA, Venohr I, et al. J Am Geriatr Soc

10 CLINIC DESCRIPTION Weekly 60 minute group visit Led by clinical pharmacist Optional minute individual appointment Standardized template to guide education and documentation Patients identified proactively by pharmacy or by provider consult Education Topics Defining an opioid overdose Learning what can cause an overdose Recognizing signs and symptoms of an overdose Learning how to prevent an overdose Steps to take as a first responder Do s and don'ts of responding to an overdose Overview of naloxone and how it works When to use and how to administration naloxone When to give a second dose of naloxone Hands on naloxone kit training

11 EXAMPLES OF CANDIDATES Veterans with high risk medical history Opioid use disorder diagnosis Prescription opioid misuse or injection opioid use History of previous opioid overdose Chronic hepatitis, cirrhosis, alcohol use disorder or other substance use disorder and taking opioid Sleep apnea or pulmonary disease and taking opioid Veterans with high risk medication history An extended-release or longacting prescription opioid 50 mg morphine equivalents per day Prescription benzodiazepine with an opioid Veterans who receive VA or non-va care in these situations HIV education/prevention program (which may provide care to injection opioid users) Syringe access program Emergency departments (e.g. for opioid overdose or intoxication) Inpatient residential care or communitybased treatment for homeless Veterans taking an opioid Primary health care (e.g. follow-up of recent opioid overdose or intoxication) United States. Department of Veterans Affairs

12 OUTCOMES Six month evaluation Total of 42 naloxone fills in 6 months (Apr 2016 Sept 2016) Average 7 prescriptions per month 33 of the 42 patients attended the SMA Improved documentation of education provided; 79% vs 70% All patients who attended the SMA had documentation completed Recent update Total of 41 naloxone fills in 4 months (Nov 2016 Feb 2017) Average 10 prescriptions per month Primary indications for use were opioid dose 100 mg MED (54%) and combination opioid and benzodiazepine (31%)

13 CONCLUSION Implementation of a SMA for opioid and naloxone education increased access to naloxone kits Higher risk patient population targeted ( 100 mg MED) Education was provided efficiently to patients by clinical pharmacists Utilization of a standardized template increased completed documentation Recommendations/Future Steps Utilizing pharmacy students to identify and contact patients categorized as high risk patients Patients prescribed buprenorphine/naloxone for opiate use disorder will be coprescribed a naloxone kit during the induction period

14 POST-TEST ASSESSMENT 1. Which education topics should be discussed with each patient prescribed a naloxone kit? a) How to determine if a second dose of naloxone is needed b) How to recognize signs and symptoms of an opioid overdose c) When and how to administer naloxone d) All of the above

15 POST-TEST ASSESSMENT 1. Which of the following patients would benefit most from a naloxone prescription based on their risk factor(s)? a) 66 y.o. male with hypothyroidism prescribed hydrocodone as needed after a motor vehicle accident b) 52 y.o. female prescribed morphine ER with a history of sleep apnea and substance use disorder c) 31 y.o. male with generalized anxiety prescribed hydroxyzine and oxycodone as needed d) 42 y.o. female prescribed oxycodone with a history of diabetes and neuropathy

16 POST-TEST ASSESSMENT 1. Which of the following is most likely to be observed after implementation of a shared medical appointment? a) Patients feel discouraged and ask fewer questions b) Patient education is provided less efficiently c) Patients report greater satisfaction with care provided d) Patient contact time with their healthcare team is decreased

17 REFERENCES Centers for Disease Control and Prevention. Prescription Drug Overdose in the United States: Fact Sheet Retrieved from: Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain United States, Centers for Disease Control and Prevention. March 18, Retrieved from: Edelman D, McDuffie JR, Oddone E, et al. Shared Medical Appointments for Chronic Medical Conditions: A Systematic Review. Department of Veterans Affairs Health Services Research & Development Service. VA-ESP Project #09-010; Jaber R, Braksmajer A, Trilling JS. Group Visits: A Qualitative Review of Current Research. J Am Board Fam Med. 2006;19(3): Oregon Health Authority. Opiate Overdose Treatment: Naloxone Training Protocol. September 22, Retrieved from: Scott JC, Conner DA, Venohr I, et al. Effectiveness of a Group Outpatient Visit Model for Chronically Ill Older Health Maintenance Organization Members: A 2-year Randomized Trial of the Cooperative Health Care Clinic. J Am Geriatr Soc. 2004;52: Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. January 15, Retrieved from: United States. Department of Veterans Affairs. Veterans Health Administration. Implementation of Opioid Overdose Education and Naloxone Distribution (OEND) to Reduce Risk of Opioid- Related Death (IL ) Washington DC: Petzel, R. United States. Department of Veterans Affairs. Veterans Health Administration. Recommendations for Issuing Naloxone Rescue for the VA Opioid Overdose Education and Naloxone Distribution (OEND) Program Washington DC: Goodman, F. Wheeler, E., Burk, K., McQuie, H., & Stancliff, S. Guide To Developing and Managing Overdose Prevention and Take-Home Naloxone Projects: Harm Reduction Coalition Retrieved from: World Health Organization. Community Management of Opioid Overdose Retrieved from:

Opioid Overdose Education and Naloxone Distribution

Opioid Overdose Education and Naloxone Distribution Opioid Overdose Education and Naloxone Distribution Emily Stoukides, PharmD PGY-2 Ambulatory Care Pharmacy Resident Nicole Brunet, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health Disclosures Emily

More information

Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration

Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office

More information

Opioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services

Opioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services Opioid Safety Initiative Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services 1 2 Opioid Safety Initiative (OSI) Overdose Education and Naloxone Distribution (OEND):

More information

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description

More information

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able

More information

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals

Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Clint Ross, PharmD, BCPP Clinical Pharmacy Specialist Psychiatry Residency Program Director Psychiatric Pharmacy Medical University

More information

Running Head: PICOT-D ASSIGNMENT 1. NURS 610: PICOT-D Assignment. Peggie L. Powell. VCU School of Nursing DNP Program

Running Head: PICOT-D ASSIGNMENT 1. NURS 610: PICOT-D Assignment. Peggie L. Powell. VCU School of Nursing DNP Program Running Head: PICOT-D ASSIGNMENT 1 NURS 610: PICOT-D Assignment Peggie L. Powell VCU School of Nursing DNP Program PICOT-D ASSIGNMENT 2 PICOT-D Component Component Wording (P)atient population Among providers

More information

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Pain Management and Safe use of opioids in hospitals Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Bronx Care Health System Bronx Lebanon Hospital Concourse/ Fulton division, Nursing

More information

TITLE AUTHORS. Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy

TITLE AUTHORS. Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy TITLE Naloxone Counseling for Harm Reduction and Patient Engagement AUTHORS Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy Marianne E. Koenig, PharmD UPMC St. Margaret Family

More information

Prescription Opioid Overdose in Oregon: A public health perspective

Prescription Opioid Overdose in Oregon: A public health perspective Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,

More information

Management of Pain - A Comparison of Current Guidelines

Management of Pain - A Comparison of Current Guidelines Management of Pain - A Comparison of Current Guidelines The Centers for Disease Control and Prevention (CDC) released a guideline in 2016 regarding the prescribing of opioids for chronic non-cancer pain

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and

More information

Addressing the Opioid Epidemic in the Veterans Health Administration

Addressing the Opioid Epidemic in the Veterans Health Administration Addressing the Opioid Epidemic in the Veterans Health Administration Julie Gochnour, MD Governor s Working Group on Veterans, Service Members, and Their Families May 25, 2017 Overview Epidemiology of the

More information

North Dakota Board of Pharmacy

North Dakota Board of Pharmacy North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives

More information

Veterans Health Administration Pharmacy Benefits Management Academic Detailing Services

Veterans Health Administration Pharmacy Benefits Management Academic Detailing Services Veterans Health Administration Pharmacy Benefits Management Academic Detailing Services Melissa Christopher, Pharm.D. National Director, Academic Detailing Services VACO PBM San Diego, California USA Academic

More information

Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders

Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders Alexander Y. Walley, MD, MSc Boston University School of Medicine ThINC Bergen 2015 Conference

More information

Opioid epidemic and PEHP

Opioid epidemic and PEHP Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe

More information

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful

More information

Oregon s PDMP: An epidemiological assist tool

Oregon s PDMP: An epidemiological assist tool Oregon s PDMP: An epidemiological assist tool Todd Beran Center for Prevention and Health Promotion Oregon Health Authority PDMP TTAC Webinar February 13, 2013 1 Acknowledgements Lisa Millet, MSH, Section

More information

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months

More information

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Robert B. Hanlin, M.D., FAAFP Vice Chair, Medical Staff Affairs Greenville Health System Greenville, SC Disclosures

More information

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4) NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau

More information

New Guidelines for Opioid Prescribing

New Guidelines for Opioid Prescribing New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research

More information

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017 Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial

More information

Veteran s Integrative Pain (VIP) Center: A program for high risk patients on chronic opioids

Veteran s Integrative Pain (VIP) Center: A program for high risk patients on chronic opioids Veteran s Integrative Pain (VIP) Center: A program for high risk patients on chronic opioids Hunter Holmes McGuire VA Richmond, VA Maggie Roma ANP-BC Clinic Administrative Coordinator Objectives Acknowledge

More information

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3) NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 218 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Managed Care Pushes for Safer Opioid Oversight

Managed Care Pushes for Safer Opioid Oversight Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging

More information

Defining the Role of the Pharmacist in Combatting the Opioid Epidemic

Defining the Role of the Pharmacist in Combatting the Opioid Epidemic Defining the Role of the Pharmacist in Combatting the Opioid Epidemic Dan Hartung, PharmD, MPH Oregon State University, College of Pharmacy Portland, OR Nicole O Kane, PharmD HeathInsight Oregon Portland,

More information

Syringe Service Programs: Platforms for Engagement. September 28, 2018 Melissa Green, MASW, LSW Harm Reduction Program Manager Columbus Public Health

Syringe Service Programs: Platforms for Engagement. September 28, 2018 Melissa Green, MASW, LSW Harm Reduction Program Manager Columbus Public Health Syringe Service Programs: Platforms for Engagement September 28, 2018 Melissa Green, MASW, LSW Harm Reduction Program Manager Columbus Public Health Strategy: Syringe Service Programs Harm Reduction focuses

More information

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South

More information

Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA

Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA Department of Veterans Affairs Network Policy No.: 2014-01 VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA CHRONIC OPIOID USE FOR NON-MALIGNANT PAIN 1. PURPOSE: To

More information

Navigating Pain Management during the Opioid Epidemic: Focus Group Findings

Navigating Pain Management during the Opioid Epidemic: Focus Group Findings Navigating Pain Management during the Opioid Epidemic: Focus Group Findings David Cameron Oregon Health & Science University Department of Family Medicine, Portland, OR Funding received from AHRQ (5R18HS024227-02)

More information

There are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014

There are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014 Maintaining Patient Safety When Chronic Opioid Therapy Is Prescribed P. David Pacheco, Ph.C, PA-C, CAAAPM Pain Medication Management Specialist Southwest Interventional Pain Specialists, PC 4700 Jefferson

More information

The Opioid Crisis in Minnesota: On the Ground Approaches. Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP

The Opioid Crisis in Minnesota: On the Ground Approaches. Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP The Opioid Crisis in Minnesota: On the Ground Approaches Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP Objectives Describe current pharmacy practices to address the opioid crisis

More information

Subject: Pain Management (Page 1 of 7)

Subject: Pain Management (Page 1 of 7) Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all

More information

The Population is Abusing Drugs, but are Drugs Abusing Insurance?

The Population is Abusing Drugs, but are Drugs Abusing Insurance? Image licensed from Shutterstock The Population is Abusing Drugs, but are Drugs Abusing Insurance? 01/30/2018 Gina C. Guzman, MD, DBIM, FALU, FLMI, VP and Chief Medical Director Tim Morant, FSA, MAAA,

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

Opioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016

Opioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016 Opioids: What You Should Know About Opioid Prescribing Denis G. Patterson, DO Nevada State Medical Association October 19, 2016 Contact Information Denis G. Patterson, DO Nevada Advanced Pain Specialists

More information

AN OVERVIEW OF THE PRESENTATION AND TREATMENT OF OPIOID OVERDOSE

AN OVERVIEW OF THE PRESENTATION AND TREATMENT OF OPIOID OVERDOSE AN OVERVIEW OF THE PRESENTATION AND TREATMENT OF OPIOID OVERDOSE Jasmine Carpenter, Pharm. D, BCPS, BCPP Clinical Pharmacy Specialist-PACT Mental Health Veterans Affairs Medical Center, Washington DC OBJECTIVES

More information

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3) NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau

More information

Quality Improvement: Evaluating a Naloxone Program

Quality Improvement: Evaluating a Naloxone Program Oregon Health & Science University OHSU Digital Commons Scholar Archive 6-29-2017 Quality Improvement: Evaluating a Naloxone Program Jennifer Herr Follow this and additional works at: http://digitalcommons.ohsu.edu/etd

More information

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction

More information

Strategies in Managing Opioid and Benzodiazepine Co-Prescribing

Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes

More information

Slide 1. Slide 2. Slide 3

Slide 1. Slide 2. Slide 3 Slide 1 Opioid Update: What s Happening at the National, State and Local Level? Susan DeVuyst-Miller, PharmD, AE-C Assistant Professor, Ferris State University Clinical Pharmacist, Cherry Health Services

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description

More information

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

Pharmacist Learning Objectives

Pharmacist Learning Objectives Opioid Overdose Education and Naloxone Distribution Keith Thornell, Pharm.D. Clinical Pharmacist Co-Occurring Disorders Pain Clinic NM Veterans Affairs Health Care System richard.thornell@va.gov 1 Pharmacist

More information

Medication Misuse and Abuse: A Growing Epidemic

Medication Misuse and Abuse: A Growing Epidemic Medication Misuse and Abuse: A Growing Epidemic Colorado Providers Association Professionalizing Prevention June 19, 2015 Mancia Ko, PharmD, MBA Associate Director, Medical Affairs,, Ameritox Assistant

More information

Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose

Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose 1 Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose March 7, 2018 Learning Objectives Differentiate the medical diagnoses that increase the risk of taking opioids Identify the

More information

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioid Use in Youth. Amy Yule M.D. March 2, Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin

More information

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any

More information

Revised 9/30/2016. Primary Care Provider Pain Management Toolkit

Revised 9/30/2016. Primary Care Provider Pain Management Toolkit Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral

More information

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies October 20, 2016 Scott K. Proescholdbell, MPH Opioid Overdose and North Carolina s Public Health and Prevention Strategies Deaths per 100,000 population Death Rates* for Three Selected Causes of Injury,

More information

Fighting the Good Fight: How to Convert Opioids Just Right!

Fighting the Good Fight: How to Convert Opioids Just Right! Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,

More information

AN INTEGRATED APPROACH TO BENZODIAZEPINE DISCONTINUATION: SHARED MEDICAL APPOINTMENTS FOR VETERANS CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES

AN INTEGRATED APPROACH TO BENZODIAZEPINE DISCONTINUATION: SHARED MEDICAL APPOINTMENTS FOR VETERANS CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES AN INTEGRATED APPROACH TO BENZODIAZEPINE DISCONTINUATION: SHARED MEDICAL APPOINTMENTS FOR VETERANS CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES Elizabeth (Betsy) Crowe, PhD Lucille J. Carriere, PhD Objectives

More information

Opioid Prescription and Illicit Drug Overdoses: On the Rise

Opioid Prescription and Illicit Drug Overdoses: On the Rise Opioid Prescription and Illicit Drug Overdoses: On the Rise Cindy Haynes, MSA-PA, CHES Chronic Pain Program Coordinator Northern Piedmont Community Care Duke Division of Community Health Objectives Define

More information

Protocol For: Personally Furnishing Naloxone. Update Log

Protocol For: Personally Furnishing Naloxone. Update Log Protocol For: Personally Furnishing Naloxone Update Log Updated By: Reason for Update: Date: Approved By: K. Benick RN Original draft 6/7/16 Pam Butler Protocol: Personally Furnishing Naloxone_Morrow County

More information

Reducing Opioid Deaths: Arizona s Emergency Declaration & Response

Reducing Opioid Deaths: Arizona s Emergency Declaration & Response Reducing Opioid Deaths: Arizona s Emergency Declaration & Response September 15, 2017 Sheila Sjolander, Assistant Director Arizona Department of Health Services Emergency Declaration On June 5, 2017, Arizona

More information

Opioid Dependence and Buprenorphine Management

Opioid Dependence and Buprenorphine Management Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale

More information

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D. Idaho DUR Board Meeting Minutes Date: January 25, 2018 Time: 9am-12:00pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: David Agler, M.D. Committee Member

More information

8.0 Take Home Naloxone

8.0 Take Home Naloxone 8.0 Take Home Naloxone 8.1 Population characteristics For the financial year (FY) 2016/17, 721 take home naloxone (THN) kits were issued in the City of Edinburgh. Of the 323 individuals who received naloxone

More information

Six Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents,

Six Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents, Six Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents, 2009-2014 Lauretta E. Grau, Russell Skip Barbour, and Shawn M. Lang Background Heroin Deaths FDA efforts

More information

Use of Opioids for Chronic Non Malignant Pain (CNMP)

Use of Opioids for Chronic Non Malignant Pain (CNMP) I. PURPOSE Use of Opioids for Chronic Non Malignant Pain (CNMP) We the Safe Opioid Prescribing and Review Committee (SOPARC) are inspired to support a shift in opioid prescribing that improves clinical

More information

Teaming Up for Safer Pain Management: Strategies for Effective Collaboration

Teaming Up for Safer Pain Management: Strategies for Effective Collaboration Teaming Up for Safer Pain Management: Strategies for Effective Collaboration Noah Nesin, MD, FAAFP, Vice President of Medical Affairs, Penobscot Community Health Care Felicity Homsted, PharmD, DPLA, Chief

More information

Scope of the Opiate Problem 6/5/18. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond. Overview.

Scope of the Opiate Problem 6/5/18. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond. Overview. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond David Anisman, MD Medical Director, Farmington Health Center (Primary Care) Associate Medical Director, Community

More information

EXTENDED RELEASE OPIOID DRUGS

EXTENDED RELEASE OPIOID DRUGS RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),

More information

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers

More information

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL Brian Fuehrlein, MD PhD VA Connecticut Healthcare System and Yale University I have no conflicts of interest or relevant financial

More information

Opioid Use: Current Challenges & Clinical Advancements

Opioid Use: Current Challenges & Clinical Advancements Opioid Use: Current Challenges & Clinical Advancements Whitney Bergquist, PharmD, MBA, BCPS Acute Care NPPA Conference February 8, 2017 2017 MFMER slide-1 No Disclosures 2017 MFMER slide-2 Objectives Summarize

More information

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m. Working with People Who Use Drugs in HIV Care Settings August 29, 2017 Workshop C 2:00 3:30 p.m. Working with People Who Use Drugs in HIV Care Settings Facilitator: Liz Hall, CDPH Office of AIDS Matt Curtis,

More information

CDC Guideline for Prescribing Opioids for Chronic Pain

CDC Guideline for Prescribing Opioids for Chronic Pain National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug

More information

Addressing the Opioid Epidemic in Tennessee

Addressing the Opioid Epidemic in Tennessee Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for

More information

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices August 25, 2017 Presented by Michael Crooks, PharmD. Medication Safety and Care Coordination Task Lead 8/28/2017

More information

THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING

THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING Ernest J Dole, PharmD, PhC, FASHP, BCPS Clinical Pharmacist University of New Mexico Hospitals And Clinical Associate Professor University

More information

4/18/2018. Disclosure Statement. Background. Learning Objectives. Background. Background

4/18/2018. Disclosure Statement. Background. Learning Objectives. Background. Background Disclosure Statement The implementation of a pharmacy run outpatient addiction clinic focusing on patients with high risk for negative outcomes with active alcohol use disorder (AUD) By Jaime Cantu April

More information

Buprenorphine Order Set and Rapid Access Referral. Copyright 2017, CAMH

Buprenorphine Order Set and Rapid Access Referral. Copyright 2017, CAMH 2 Buprenorphine Order Set and Rapid Access Referral 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives Solution

More information

Naloxone and Combating the Opioid Epidemic

Naloxone and Combating the Opioid Epidemic Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to

More information

Chronic Pain: Decreasing Dependence on Opioids

Chronic Pain: Decreasing Dependence on Opioids University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Chronic Pain: Decreasing Dependence on Opioids Derek Luzim Follow this and additional

More information

Prescription Drug Misuse/Abuse in Seniors. April Rovero Founder/Executive Director

Prescription Drug Misuse/Abuse in Seniors. April Rovero Founder/Executive Director Prescription Drug Misuse/Abuse in Seniors April Rovero Founder/Executive Director Deaths per 100,000 Population 30 25 Overdose Demographics Drug Poisoning Death Rates by Age: United States (2010) 20 15

More information

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC Opioid Use Disorders and Their Treatment Mark Edlund, MD, PhD RTI International Photo courtesy of The Herb Museum, Vancouver, BC Acknowledgements Funded by NIDA R01 DA022560-01 NIDA R01 DA034627 NIDA R01

More information

ROOM project Addressing the Opioid Epidemic in the U.P. Presented by; Kevin L. Piggott, MD, MPH May 21, 2018

ROOM project Addressing the Opioid Epidemic in the U.P. Presented by; Kevin L. Piggott, MD, MPH May 21, 2018 ROOM project Addressing the Opioid Epidemic in the U.P. Presented by; Kevin L. Piggott, MD, MPH May 21, 2018 REDUCING OPIOID OVERDOSE IN MARQUETTE COUNT Y (ROOM) Funding provided by the CDC to the Michigan

More information

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions

More information

New Guidelines for Prescribing Opioids

New Guidelines for Prescribing Opioids New Guidelines for Prescribing Opioids Keeping Your Claimants Safe Presented by: Dr. Mitch Freeman, Pharm.D. Chief Clinical Officer, Pharmacy Solutions Agenda The Opioid Challenge Today How We Got Here

More information

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention Understanding the Epidemic When the Prescription Becomes the Problem In a period of nine months, a tiny Kentucky county

More information

Naloxone: Preventing Opioid Overdose in the Community. Sharon Stancliff, MD Medical Director Harm Reduction Coalition

Naloxone: Preventing Opioid Overdose in the Community. Sharon Stancliff, MD Medical Director Harm Reduction Coalition Naloxone: Preventing Opioid Overdose in the Community Sharon Stancliff, MD Medical Director Harm Reduction Coalition DISCLOSURES Sharon Stancliff MD has nothing to disclose LEARNING OBJECTIVES 1. Discuss

More information

Walking the Line: Opioid Dose De-escalation

Walking the Line: Opioid Dose De-escalation Walking the Line: Opioid Dose De-escalation Courtney Kominek, PharmD, BCPS, CPE Disclosures Axial Healthcare Consultant Daiichi Sankyo Honoraria The views and opinions expressed in this presentation are

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

Opioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative

Opioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative Opioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative Objectives Summarize the current crisis at the national and Iowa state level.

More information

OPIOID PRESCRIBING RULES. May 17, 2017 Webinar

OPIOID PRESCRIBING RULES. May 17, 2017 Webinar OPIOID PRESCRIBING RULES May 17, 2017 Webinar Outline Introduction and Universal Precautions Dr. Levine, Commissioner, Health Department 15 Minutes Acute Pain Dr. Patti Fisher, UVMMC 20 Minutes Chronic

More information

The Opioid Addiction Emergency In Virginia June 8, 2017

The Opioid Addiction Emergency In Virginia June 8, 2017 The Opioid Addiction Emergency In Virginia June 8, 2017 Marissa J. Levine, MD MPH State Health Commissioner Virginia Department of Health Chronic Disease of Addiction Definition: A primary, chronic disease

More information

Partnership HealthPlan of California s Managing Pain Safely Program Robert Moore, MD MPH Chief Medical officer Partnership HealthPlan of California

Partnership HealthPlan of California s Managing Pain Safely Program Robert Moore, MD MPH Chief Medical officer Partnership HealthPlan of California Session L6 This presenter has nothing to disclose It Takes a Village to Curb the Prescription Opioid Epidemic: Partnership HealthPlan of California s Managing Pain Safely Program Robert Moore, MD MPH Chief

More information

Coalition Strategies Across The Continuum of Care

Coalition Strategies Across The Continuum of Care Coalition Strategies Across The Continuum of Care Dorothy J. Chaney M.Ed. CADCA Consultant Building Safe, Healthy, and Drug Free Communities Overview and Objectives: By completing this training participants

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2099-5 Program Prior Authorization/Medical Necessity Buprenorphine Products (Pain Indications) Medication Belbuca (buprenorphine

More information

1/30/2017 SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT ACPE PRE-TEST QUESTIONS. I have no declarations.

1/30/2017 SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT ACPE PRE-TEST QUESTIONS. I have no declarations. SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT Traci Hamer, PharmD, MAT Kaiser Permanente Northwest Pain Management Pharmacy Services I have no declarations. ACPE PRE-TEST QUESTIONS True/False: Opioids

More information